NasdaqCM - Delayed Quote USD

Regencell Bioscience Holdings Limited (RGC)

685.85

+45.85

+(7.16%)

At close: June 6 at 4:00:00 PM EDT

690.00

+4.15

+(0.61%)

After hours: June 6 at 7:52:25 PM EDT

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Name	Title	Pay	Exercised	Year Born
Mr. Yat-Gai Au	Founder, Chairman & CEO	--	--	1973
Ms. Michelle Chan	Financial Controller & Principal Financial Officer	--	--	--
Mr. Wai Hong Chung	COO, Chief Strategy Officer & Director	245.64k	--	1977
Ms. Antonia Assang	Senior Vice President of Project Management	--	--	--
Mr. Yat-Pui Au	Chief Business Officer	--	--	1974

Chinachem Leighton Plaza

9th Floor 29 Leighton Road

Causeway Bay

Hong Kong

852 2155 0823 https://www.regencellbioscience.com

Sector:: Healthcare
Industry:
Full Time Employees:: 12

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Regencell Bioscience Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events Information Not Available

June 2, 2025 at 12:00 AM UTC